Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005632 | 0.80 | CES2 (0.58) | CES2CES1SRD5A2GSK3BPTPN1 | |
| SCHEMBL3763045 | 0.78 | CES2 (0.56) | CES2CES1SRD5A2GSK3BPTPN1 | |
| SCHEMBL28331909 | 0.76 | CES2 (0.54) | CES2CES1SRD5A2GSK3BPTPN1 | |
| SCHEMBL2289144 | 0.76 | CES2 (0.67) | CES2CES1SRD5A2GSK3BPTPN1 | |
| SCHEMBL1119543 | 0.76 | CES2 (0.54) | CES2CES1SRD5A2IDO1HPGD | |
| SCHEMBL5206631 | 0.76 | CES2 (0.54) | CES2CES1SRD5A2GSK3BPTPN1 | |
| Hydrochloric Acid SCHEMBL27491061 | 0.74 | PRSS1 (0.54) | CES2CES1IDO1HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL1549707 | 0.74 | PRSS1 (0.54) | CES2CES1IDO1HPGDKMT2A | |
| SCHEMBL4088597 | 0.74 | CES2 (0.64) | CES2CES1SRD5A2GSK3BPTPN1 | |
| SCHEMBL349343 | 0.73 | CES2 (0.70) | CES2CES1SRD5A2GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022189856-A9 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2022-10-13 | — | — | WO | disclosed |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2011-10-13 | — | — | US | disclosed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-7652061-B2 | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1638963-B1 | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-7538135-B2 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2009-05-26 | — | — | US | disclosed |
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2009-05-07 | — | — | US | disclosed |
| US-20080221336-A1 | Pparalpha/Gamma Agonists and Processes of Preparing | GARRETT CHRISTINE E | 2008-09-11 | — | — | US | disclosed |
| US-20080131475-A1 | Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds | COHEN DAVID SAUL | 2008-06-05 | — | — | US | disclosed |
| US-20070299047-A1 | Combination of Organic Compounds | MAHER WILLIAM | 2007-12-27 | — | — | US | disclosed |
| EP-1448523-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW T | 2007-06-14 | — | — | US | disclosed |
| US-7183304-B2 | such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents | NOVARTIS AG (CH) | 2007-02-27 | — | — | US | disclosed |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| WO-2006084757-A2 | COMBINATION OF CA/MG SALT OF VALSARTAN WITH AN ANTIDIABETIC AGENT | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006029349-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | CES2 1539/4885CES1 159/4885SRD5A2 970/4885 |
| US-20100152255-A1 | Organic Compounds | PPARG, FABP2, PPARA | CES2 1269/4885CES1 206/4885SRD5A2 416/4885 |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | CES2 1539/4885CES1 159/4885SRD5A2 970/4885 |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | CES2 1539/4885CES1 159/4885SRD5A2 970/4885 |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | PPARG, PPARA, PPARD | CES2 2565/4885CES1 251/4885SRD5A2 1394/4885 |
| US-20070299047-A1 | Combination of Organic Compounds | GLP1R, PPARG, GCGR | CES2 2139/4885CES1 118/4885SRD5A2 404/4885 |
| US-20080221336-A1 | Pparalpha/Gamma Agonists and Processes of Preparing | PPARA, PPARG, PPARD | CES2 2230/4885CES1 414/4885SRD5A2 150/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | CES2 2646/4885CES1 289/4885SRD5A2 1032/4885 |
| US-20080131475-A1 | Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds | PPARA, PPARD, PPARG | CES2 1866/4885CES1 1159/4885SRD5A2 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.